CD16A and TAA targeted therapy (PersonGen Biotherapeutics)

N/A

Report date: 2025/03/03 15:37:15

Base Information

Drug NameCD16A and TAA targeted therapy (PersonGen Biotherapeutics)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III-A modulatorsTumor-associated antigen modulators
TargetsLow affinity immunoglobulin gamma Fc region receptor III-ATumor-associated antigen
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A